Bone and lung are the two most frequent sites of metastatic recurrence in breast cancer. In work supported by this grant we selected organ-specific metastasis cell subpopulations from the breast carcinoma cell line MDA-MB-231, and derived a bone metastasis gene expression signature (BoMS) and a lung metastasis signature (LMS). We functionally validated many of these genes as mediators of bone or lung metastasis. With W. Gerald and A. Olshen, we showed the ability of these signatures to predict site of relapse in cohorts of primary breast tumors. We are defining the functions that are fulfilled by these genes, including roles of BoMS genes IL11 and OPN in osteoclast activation during osteolytic metastasis, and roles of LMS genes Epiregulin, COX2, MMP1 and MMP2 in tumor neovascularization and metastatic extravasation. With R. Benezra and H. Varmus we are defining the role of LMS gene ID1 in conferring tumor-initiating capacity to metastatic breast cancers of the basal subtype. Based on these insights, we have proposed with L. Norton the "tumor self-seeding" hypothesis of how certain metastatic functions may underlie the association of large tumor size, rapid growth rate, and metastatic behavior often seen in clinical cancer. Additionally, we have defined mechanisms that allow breast cancer cells to avert the tumor-suppressive action of TGFR. Using mouse models developed under P01-CA94060, we demonstrated roles of the TGFIJ-Smad pathway in breast cancer metastasis to lung and bone. These models and target genes provide relevant assay systems to test the effectiveness of existing and novel drugs against breast cancer metastasis. Building on this progress, in the next grant period we are planning to identify new bone and lung metastasis genes using primary malignant cells from fresh pleural effusions (Aim 1). We will seek to define functional and therapeutically relevant interactions between validated metastasis genes (Aim 2). We will identify clinically relevant genes mediating the pro-metastatic action of TGFB in lung and bone (Aim 3). Furthermore, we will experimentally test the "tumor self-seeding" hypothesis (Aim 4). Built into each of these specific aims is the development and application of relevant assay systems to test the effectiveness of therapeutic agents under study in the Program Project. In sum, we are proposing to continue on the pace of discovery in breast cancer metastasis that was initiated during the previous grant period by this cooperative research effort.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA094060-10
Application #
8382394
Study Section
Special Emphasis Panel (ZCA1-RPRB-O)
Project Start
Project End
2014-04-30
Budget Start
2012-05-01
Budget End
2013-04-30
Support Year
10
Fiscal Year
2012
Total Cost
$451,618
Indirect Cost
$213,423
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Chen, Qing; Boire, Adrienne; Jin, Xin et al. (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533:493-8
Kass, Elizabeth M; Lim, Pei Xin; Helgadottir, Hildur R et al. (2016) Robust homology-directed repair within mouse mammary tissue is not specifically affected by Brca2 mutation. Nat Commun 7:13241
Gao, Hua; Chakraborty, Goutam; Zhang, Zhanguo et al. (2016) Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. Cell 166:47-62
Ebbesen, Saya H; Scaltriti, Maurizio; Bialucha, Carl U et al. (2016) Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomas. Proc Natl Acad Sci U S A 113:3030-5
Malladi, Srinivas; Macalinao, Danilo G; Jin, Xin et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165:45-60
She, Qing-Bai; Gruvberger-Saal, Sofia K; Maurer, Matthew et al. (2016) Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer. BMC Cancer 16:587
Yang, C; Li, Z; Bhatt, T et al. (2016) Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence. Oncogene :
Rodrik-Outmezguine, Vanessa S; Okaniwa, Masanori; Yao, Zhan et al. (2016) Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor. Nature 534:272-6
Obenauf, Anna C; Zou, Yilong; Ji, Andrew L et al. (2015) Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 520:368-72
Okada, Tomoyo; Sinha, Surajit; Esposito, Ilaria et al. (2015) The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling. Nat Cell Biol 17:81-94

Showing the most recent 10 out of 96 publications